Akebia Therapeutics, Inc. (AKBA) Stock Overview
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
✓ Sourced directly from Yahoo Finance · Checked for accuracy at every rebuild · Snapshot: 6 September 2026
About Akebia Therapeutics, Inc.
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to…
Source: Yahoo Finance
Sector & Industry
Akebia Therapeutics, Inc. operates in the Healthcare sector, within the Drug Manufacturers - Specialty & Generic industry group. It is listed on the NASDAQ exchange.
Akebia Therapeutics, Inc. at a Glance
| Company | Akebia Therapeutics, Inc. |
| Ticker | AKBA |
| Exchange | NASDAQ |
| Currency | USD |
| Price | $0.97 |
| Market cap | $270.10M |
| P/E ratio (trailing) | — |
| EPS (trailing) | -$0.12 |
| 52-week high | $3.20 |
| 52-week low | $0.81 |
| Dividend yield | — |
| Ex-dividend date | — |
| Beta | 0.19 |
| Return on equity (ROE) | -109.38% |
| Debt-to-equity | 796.18% |
| Average volume | 6.25M |
| Shares outstanding | 277.11M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Employees | 194 |
| Country | United States |
Investing Essentials
As an Amazon Associate we earn from qualifying purchases. Links below are affiliate links.
Evaluating pharma pipelines, devices and healthcare economics.
Check Price →Benjamin Graham's classic on value investing — the book Warren Buffett calls the best ever written on the subject.
Check Price →Peter Lynch on how everyday investors can spot winners before the professionals do.
Check Price →Frequently Asked Questions
- What is Akebia Therapeutics, Inc.'s current P/E ratio?
- Akebia Therapeutics, Inc. (AKBA) has a trailing P/E ratio of — as of our 6 September 2026 data snapshot. Learn what the P/E ratio means →
- What is Akebia Therapeutics, Inc.'s market capitalisation?
- Akebia Therapeutics, Inc.'s market cap is $270.10M based on our latest snapshot. See how it ranks by market cap →
- What is AKBA's 52-week range?
- Over the past 52 weeks, AKBA has traded between $0.81 and $3.20. What does the 52-week range mean? →
- How volatile is Akebia Therapeutics, Inc. compared to the market?
- Akebia Therapeutics, Inc. has a beta of 0.19, meaning it has historically moved less than the broader market. What does beta measure? →
- Does Akebia Therapeutics, Inc. pay a dividend?
- Akebia Therapeutics, Inc. does not currently pay a dividend according to our latest data.
- What exchange is AKBA listed on?
- AKBA is listed on the NASDAQ. Browse all NASDAQ-listed stocks →
- What sector is Akebia Therapeutics, Inc. in?
- Akebia Therapeutics, Inc. is classified in the Healthcare sector. Compare with Healthcare peers →
Prefer raw numbers at a glance? Browse our size and reference charts for quick lookups.
Many readers keep a stock investing journal to log positions and theses alongside pages like this one, and a dedicated financial calculator to hand for quick valuation maths.
Recommended Reading & Tools
Morgan Housel's short lessons on behaviour, luck and long-term wealth.
Check Price →Philip Fisher on what makes a business worth owning for the long term.
Check Price →Burton Malkiel's evidence-based guide to markets, indexing and long-term strategy.
Check Price →